TABLE 2.
BASELINE CHARACTERISTICS OF PATIENTS WHO CONTINUED VERSUS DISCONTINUED IBUPROFEN THERAPY
| Continued | Discontinued | P Value* | |
|---|---|---|---|
| Baseline age (yr), mean ± SD (n) | 9.2 ± 2.9 (411) | 10.6 ± 3.2 (954) | <0.0001 |
| 6–12 yr, % | 86.6 | 75.2 | <0.0001 |
| 13–18 yr, % | 13.4 | 24.8 | |
| Male, % | 52.6 | 47.9 | 0.12 |
| Baseline FEV1 percent predicted, mean ± SD (n) | 93.7 ± 16.1 (411) | 91.3 ± 15.5 (954) | 0.0147 |
| 60–79%pred, % | 22.4 | 25.8 | 0.17 |
| 80–89%pred, % | 17.5 | 20.6 | |
| 90–99%pred, % | 26.5 | 23.2 | |
| ⩾100%pred, % | 33.6 | 30.4 | |
| Weight-for-age percentile, mean ± SD (n) | 38.7 ± 26.5 (411) | 35.5 ± 26.2 (954) | 0.037 |
| Pseudomonas aeruginosa infection | |||
| Never infected, % | 15.6 | 11.9 | 0.058 |
| Infected after baseline, % | 23.6 | 22.0 | |
| Always infected, % | 59.9 | 63.4 | |
| Unknown baseline, later positive, % | 1.0 | 2.6 | |
| Hospitalizations in prior year, mean ± SD (n) | 0.26 ± 0.78 (388) | 0.40 ± 0.83 (913) | 0.0004 |
| Median annual income ($), mean ± SD (n) | 47,538 ± 17,694 (402) | 48,957 ± 17,995 (924) | 0.13 |
| No or state/federal insurance only, % | 19.0 | 20.7 | 0.48 |
| Inhaled tobramycin use | |||
| At baseline, % | 21.2 | 14.5 | 0.0022 |
| Ever during follow-up, % | 74.7 | 77.6 | 0.25 |
| Dornase alfa use | |||
| At baseline, % | 45.5 | 53.2 | 0.0086 |
| Ever during follow-up, % | 75.2 | 80.9 | 0.017 |
*
P values from Wilcoxon rank sum test or chi-square test.